Advertisement

Comparative Effectiveness of Lymphadenectomy Strategies During Curative Resection for Gastric Adenocarcinoma

  • Yinin Hu
  • Timothy L. McMurry
  • Bernadette Goudreau
  • Katie M. Leick
  • Tri M. Le
  • Victor M. ZaydfudimEmail author
Original Article
  • 25 Downloads

Abstract

Background

The purpose of this study was to compare the long-term effectiveness of three lymphadenectomy strategies in patients with gastric cancer. We hypothesized that, compared with the traditional standard (D2) lymph node dissection strategy, the less aggressive modified standard (mD2) lymphadenectomy may offer superior effectiveness due to reduced operative morbidity and comparable long-term recurrence-free survival.

Methods

A Markov decision analysis model was created to simulate 5-year outcomes across three lymphadenectomy approaches for gastric cancer: limited regional (D1), traditional standard (D2), and modified standard (mD2). The primary outcome was discounted quality-adjusted life-years (dQALY). Model variable estimates were derived from outcomes data and quality of life estimates published in Europe and America within the last 15 years. One-way and probabilistic sensitivity analyses were performed for clinically relevant variables.

Results

The mD2 lymphadenectomy offered 3.03 dQALY over 5 years, outperforming D2 (2.62 dQALY) and D1 (2.37 dQALY). Monte Carlo simulations indicated that both mD2 and D2 lymph node dissection strategies outperformed D1 in 94.9% of simulations. Sensitivity analyses demonstrated that the mD2 approach would be less effective than D2 if the perioperative mortality rate of mD2 was greater than 6.9% (3.2% baseline).

Conclusions

Across modern series, the modified standard mD2 lymphadenectomy is an effective alternative to the traditional D2 lymphadenectomy for patients with gastric cancer. A D1-limited regional lymphadenectomy is not recommended during gastric cancer resection.

Keywords

Gastric cancer Stomach neoplasms Gastrectomy Stomach/surgery Lymph node excision 

Notes

Statement of Author Contribution

Category 1

Conception and design of study: Hu, Le, Zaydfudim

Acquisition of data: Hu, Goudreau, Leick

Analysis and/or interpretation of data: Hu, McMurry, Le, Zaydfudim

Category 2

Drafting the manuscript: Hu, Goudreau, Leick

Revising the manuscript critically for important intellectual content: McMurry, Le, Zaydfudim

Category 3

Final approval of the version of the manuscript to be published: Hu, Goudreau, Leick, McMurry, Le, Zaydfudim

Category 4

Agreement to be accountable for all aspects of the work: Hu, Goudreau, Leick, McMurry, Le, Zaydfudim

Funding Information

This work was supported by the L30 CA220861 Award from National Cancer Institute and Grant #IRG 81-001-26 from the American Cancer Society to VMZ and by the Institutional National Research Service Award T32 CA 163177 from the National Cancer Institute to BG and KL.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.CrossRefGoogle Scholar
  2. 2.
    American Cancer Society, ed. Global cancer facts & figures. 3rd ed. Atlanta: American Cancer Society; 2015.Google Scholar
  3. 3.
    Charalampakis N, Economopoulou P, Kotsantis I, et al. Medical management of gastric cancer: A 2017 update. Cancer Med. 2018;7(1):123–133.CrossRefGoogle Scholar
  4. 4.
    Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol. 2003;21(23 Suppl):274s–275s.CrossRefGoogle Scholar
  5. 5.
    Bando E, Makuuchi R, Irino T, Tanizawa Y, Kawamura T, Terashima M. Validation of the prognostic impact of the new tumor-node-metastasis clinical staging in patients with gastric cancer. Gastric Cancer. 2018.Google Scholar
  6. 6.
    Bickenbach K, Strong VE. Comparisons of gastric cancer treatments: East vs. west. J Gastric Cancer. 2012;12(2):55–62.CrossRefGoogle Scholar
  7. 7.
    Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–449.CrossRefGoogle Scholar
  8. 8.
    Talaiezadeh AH, Asgari M, Zargar MA. Mortality and morbidity and disease free survival after D1 and D2 gastrectomy for stomach adenocarcinomas. Asian Pac J Cancer Prev. 2015;16(13):5253–5256.CrossRefGoogle Scholar
  9. 9.
    Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. surgical co-operative group. Br J Cancer. 1999;79(9–10):1522–1530.CrossRefGoogle Scholar
  10. 10.
    Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101(2):23–31.CrossRefGoogle Scholar
  11. 11.
    Petrelli NJ. The debate is over; it’s time to move on. J Clin Oncol. 2004;22(11):2041–2042.CrossRefGoogle Scholar
  12. 12.
    Strong VE, Song KY, Park CH, et al. Comparison of gastric cancer survival following R0 resection in the united states and korea using an internationally validated nomogram. Ann Surg. 2010;251(4):640–646.CrossRefGoogle Scholar
  13. 13.
    Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: Data from a large US-population database. J Clin Oncol. 2005;23(28):7114–7124.CrossRefGoogle Scholar
  14. 14.
    Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol. 2007;14(2):317–328.CrossRefGoogle Scholar
  15. 15.
    Bouvier AM, Haas O, Piard F, Roignot P, Bonithon-Kopp C, Faivre J. How many nodes must be examined to accurately stage gastric carcinomas? results from a population based study. Cancer. 2002;94(11):2862–2866.CrossRefGoogle Scholar
  16. 16.
    Lam S, Tan E, Menezes A, et al. A comparison of the operative outcomes of D1 and D2 gastrectomy performed at a single western center with multiple surgeons: A retrospective analysis with propensity score matching. World J Surg Oncol. 2018;16(1):136-018-1422-6.CrossRefGoogle Scholar
  17. 17.
    Morgan JW, Ji L, Friedman G, Senthil M, Dyke C, Lum SS. The role of the cancer center when using lymph node count as a quality measure for gastric cancer surgery. JAMA Surg. 2015;150(1):37–43.CrossRefGoogle Scholar
  18. 18.
    Rosa F, Costamagna G, Doglietto GB, Alfieri S. Classification of nodal stations in gastric cancer. Transl Gastroenterol Hepatol. 2017;2:2.CrossRefGoogle Scholar
  19. 19.
    Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 dutch patients. Lancet. 1995;345(8952):745–748.CrossRefGoogle Scholar
  20. 20.
    Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial. the surgical cooperative group. Lancet. 1996;347(9007):995–999.CrossRefGoogle Scholar
  21. 21.
    Degiuli M, Sasako M, Ponti A, Italian Gastric Cancer Study Group. Morbidity and mortality in the italian gastric cancer study group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97(5):643–649.CrossRefGoogle Scholar
  22. 22.
    Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.CrossRefGoogle Scholar
  23. 23.
    Sano T, Sasako M, Mizusawa J, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017;265(2):277–283.CrossRefGoogle Scholar
  24. 24.
    Biffi R, Chiappa A, Luca F, et al. Extended lymph node dissection without routine spleno-pancreatectomy for treatment of gastric cancer: Low morbidity and mortality rates in a single center series of 250 patients. J Surg Oncol. 2006;93(5):394–400.CrossRefGoogle Scholar
  25. 25.
    Barry JD, Blackshaw GR, Edwards P, et al. Western body mass indices need not compromise outcomes after modified D2 gastrectomy for carcinoma. Gastric Cancer. 2003;6(2):80–85.Google Scholar
  26. 26.
    Galizia G, Lieto E, De Vita F, et al. Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis. Surgery. 2015;157(2):285–296.CrossRefGoogle Scholar
  27. 27.
    Edwards P, Blackshaw GR, Lewis WG, Barry JD, Allison MC, Jones DR. Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma. Br J Cancer. 2004;90(10):1888–1892.CrossRefGoogle Scholar
  28. 28.
    Jongerius EJ, Boerma D, Seldenrijk KA, et al. Role of omentectomy as part of radical surgery for gastric cancer. Br J Surg. 2016;103(11):1497–1503.CrossRefGoogle Scholar
  29. 29.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefGoogle Scholar
  30. 30.
    Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–1957.CrossRefGoogle Scholar
  31. 31.
    Lamb P, Sivashanmugam T, White M, Irving M, Wayman J, Raimes S. Gastric cancer surgery--a balance of risk and radicality. Ann R Coll Surg Engl. 2008;90(3):235–242.CrossRefGoogle Scholar
  32. 32.
    Gosselin-Tardif A, Lie J, Nicolau I, et al. Gastrectomy with extended lymphadenectomy: A north american perspective. J Gastrointest Surg. 2018;22(3):414–420.CrossRefGoogle Scholar
  33. 33.
    Randle RW, Swords DS, Levine EA, et al. Optimal extent of lymphadenectomy for gastric adenocarcinoma: A 7-institution study of the U.S. gastric cancer collaborative. J Surg Oncol. 2016;113(7):750–755.CrossRefGoogle Scholar
  34. 34.
    Kung CH, Song H, Ye W, et al. Extent of lymphadenectomy has no impact on postoperative complications after gastric cancer surgery in sweden. Chin J Cancer Res. 2017;29(4):313–322.CrossRefGoogle Scholar
  35. 35.
    Rowen D, Brazier J, Young T, et al. Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health. 2011;14(5):721–731.CrossRefGoogle Scholar
  36. 36.
    Kobayashi D, Kodera Y, Fujiwara M, Koike M, Nakayama G, Nakao A. Assessment of quality of life after gastrectomy using EORTC QLQ-C30 and STO22. World J Surg. 2011;35(2):357–364.CrossRefGoogle Scholar
  37. 37.
    Kim AR, Cho J, Hsu YJ, et al. Changes of quality of life in gastric cancer patients after curative resection: A longitudinal cohort study in korea. Ann Surg. 2012;256(6):1008–1013.CrossRefGoogle Scholar
  38. 38.
    Avery K, Hughes R, McNair A, Alderson D, Barham P, Blazeby J. Health-related quality of life and survival in the 2 years after surgery for gastric cancer. Eur J Surg Oncol. 2010;36(2):148–154.CrossRefGoogle Scholar
  39. 39.
    Wang SJ, Fuller CD, Choi M, Thomas CR. A cost-effectiveness analysis of adjuvant chemoradiotherapy for resected gastric cancer. Gastrointest Cancer Res. 2008;2(2):57–63.Google Scholar
  40. 40.
    Murphy JD, Chang DT, Abelson J, et al. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer. 2012;118(4):1119–1129.CrossRefGoogle Scholar
  41. 41.
    Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–144.CrossRefGoogle Scholar
  42. 42.
    Hu Y, Johnston LE, Shami VM, et al. Comparative effectiveness of resection vs surveillance for pancreatic branch duct intraductal papillary mucinous neoplasms with worrisome features. JAMA Surg. 2018;153(3):225–232.CrossRefGoogle Scholar
  43. 43.
    Hu Y, Puri V, Shami VM, Stukenborg GJ, Kozower BD. Comparative effectiveness of esophagectomy versus endoscopic treatment for esophageal high-grade dysplasia. Ann Surg. 2016;263(4):719–726.CrossRefGoogle Scholar
  44. 44.
    Mocellin S, McCulloch P, Kazi H, Gama-Rodrigues JJ, Yuan Y, Nitti D. Extent of lymph node dissection for adenocarcinoma of the stomach. Cochrane Database Syst Rev. 2015;(8):CD001964. doi(8):CD001964.Google Scholar
  45. 45.
    Li SS, Costantino CL, Rattner DW, Mullen JT. Outcomes of extended lymphadenectomy for gastroesophageal carcinoma: A large western series. J Am Coll Surg. 2019;228(6):879–891.CrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2019

Authors and Affiliations

  1. 1.Department of Surgery, Division of Surgical OncologyUniversity of Virginia School of MedicineCharlottesvilleUSA
  2. 2.Department of Public Health SciencesUniversity of Virginia School of MedicineCharlottesvilleUSA
  3. 3.Surgical Outcomes Research CenterUniversity of Virginia School of MedicineCharlottesvilleUSA
  4. 4.Division of Hematology and OncologyUniversity of Virginia School of MedicineCharlottesvilleUSA

Personalised recommendations